Breaking silence: a survey of barriers to goals of care discussions from the perspective of oncology practitioners

by Katrina Lynn Piggott, Ameen Patel, Arthur Wong, Leslie Martin, Alexandra Patel, Matthew Patel, Yudong Liu, Sukhbinder Dhesy-Thind, John J. You
Published 2019-02-01

Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage...

by Arif Awan, Terry Ng, Henry Conter, William Raskin, Carol Stober, Demetrios Simos, Greg Pond, Sukhbinder Dhesy-Thind, Mihaela Mates, Vikaash Kumar, Dean Fergusson, Brian Hutton, Deanna Saunders, Lisa Vandermeer, Mark Clemons
Published 2021-02-01

Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours

by Mira M. Shenouda, Amy Gillgrass, Tina Nham, Richard Hogg, Amanda J. Lee, Marianne V. Chew, Mahsa Shafaei, Craig Aarts, Dean A. Lee, John Hassell, Anita Bane, Sukhbinder Dhesy-Thind, Ali A. Ashkar
Published 2017-07-01

Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors

by Ana L. Portillo, Richard Hogg, Sophie M. Poznanski, Eduardo A. Rojas, Niamh J. Cashell, Joanne A. Hammill, Marianne V. Chew, Mira M. Shenouda, Tyrah M. Ritchie, Quynh T. Cao, Jeremy A. Hirota, Sukhbinder Dhesy-Thind, Jonathan L. Bramson, Ali A. Ashkar
Published 2021-06-01

Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity

by Darryl P. Leong, MBBS, MPH, MBiostat, PhD, Tammy Cosman, PhD, Muhammad M. Alhussein, MD, Nidhi Kumar Tyagi, MBChB, Sarah Karampatos, MS, Carly C. Barron, MD, MS, Douglas Wright, MD, Vikas Tandon, MD, Patrick Magloire, MD, Philip Joseph, MD, David Conen, MD, MPH, P.J. Devereaux, MD, PhD, Peter M. Ellis, MBBS, MMed, PhD, Som D. Mukherjee, MD, MS, Sukhbinder Dhesy-Thind, MD, MS
Published 2019-09-01